KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Debt (2016)

Vertex Pharmaceuticals (VRTX) has 6 years of Total Debt data on record, last reported at $300.0 million in Q4 2016.

  • For Q4 2016, Total Debt rose 34.01% year-over-year to $300.0 million; the TTM value through Dec 2016 reached $300.0 million, up 34.01%, while the annual FY2016 figure was $300.0 million, 34.01% up from the prior year.
  • Total Debt reached $300.0 million in Q4 2016 per VRTX's latest filing, up from $297.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $300.0 million in Q4 2016 and bottomed at $223.9 million in Q4 2015.
  • Average Total Debt over 3 years is $288.8 million, with a median of $294.8 million recorded in 2015.
  • Peak YoY movement for Total Debt: dropped 24.06% in 2015, then soared 34.01% in 2016.
  • A 3-year view of Total Debt shows it stood at $294.8 million in 2014, then decreased by 24.06% to $223.9 million in 2015, then surged by 34.01% to $300.0 million in 2016.
  • Per Business Quant database, its latest 3 readings for Total Debt were $300.0 million in Q4 2016, $297.8 million in Q3 2016, and $296.5 million in Q2 2016.